S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Investors Scrutinize Lucid Group Over Alleged Misleading Statements

Investors who purchased Lucid Group, Inc. securities between February 25 and April 13, 2026, face a July 28 deadline to apply as lead plaintiff in an ongoing securities fraud class action. The lawsuit alleges that the electric vehicle manufacturer concealed critical supplier issues that hindered deliveries of its Gravity model.

Investors Scrutinize Lucid Group Over Alleged Misleading Statements
Photo: Bio & News

The legal action, initiated by the Rosen Law Firm, centers on claims that Lucid executives misrepresented the company’s manufacturing capacity and operational health. Plaintiffs contend that undisclosed supplier quality problems significantly disrupted the rollout of the Lucid Gravity, resulting in a material negative impact on the company's financial performance. According to the complaint, these omissions rendered the company's public statements during the period materially false and misleading.

While a lawsuit has been filed, no class has been certified yet. Investors are not currently represented by counsel unless they actively retain a firm. Those who purchased Lucid securities during the specified window may participate in the litigation under a contingency fee arrangement, which requires no out-of-pocket costs. Participation as a lead plaintiff is optional, and shareholders retain the right to remain absent class members or select their own legal representation.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!